Compare TARA & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TARA | DPRO |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.5M | 230.7M |
| IPO Year | 2014 | 2019 |
| Metric | TARA | DPRO |
|---|---|---|
| Price | $5.23 | $5.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $23.60 | $15.00 |
| AVG Volume (30 Days) | 581.6K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | $158.69 |
| Revenue Next Year | N/A | $131.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.77 | $1.63 |
| 52 Week High | $7.82 | $14.37 |
| Indicator | TARA | DPRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 52.10 |
| Support Level | $4.92 | $4.36 |
| Resistance Level | $5.44 | $7.07 |
| Average True Range (ATR) | 0.27 | 0.40 |
| MACD | 0.05 | 0.16 |
| Stochastic Oscillator | 60.14 | 94.82 |
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.